Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Percentage of vascular endothelial growth factor, endothelial nitric oxide synthase and hypoxia-inducible factor 1-alpha positive cells in essential thrombocythemia and multiple myeloma (before and after chemotherapy) on bone marrow biopsy samples of the patient compared to normal controls

From: The emergence of non-secretory multiple myeloma during the non-cytotoxic treatment of essential thrombocythemia: a case report

% Vascular endothelial growth factor Endothelial nitric oxide synthase Hypoxia-inducible factor 1-alpha cytoplasmic/nuclear
Control 8 8.19 9.84 / 4.05
Essential thrombocythemia 7.39 8.08 8.15 / 0
Multiple myeloma 20.41 5.08 1.91 / 8.18
Multiple myeloma+chemotherapy 22.68 21.94 6.3 / 9.91